Chronic Heart Failure — Right Ventricular Dysfunction in Chronic Heart Failure
Citation(s)
Barilli M, Tavera MC, Valente S, Palazzuoli A Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF. Int J Mol Sci. 2022 Apr 20;23(9):4554. doi: 10.3390/ijms23094554.
Drazner MH, Rame JE, Stevenson LW, Dries DL Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001 Aug 23;345(8):574-81. doi: 10.1056/NEJMoa010641.
Furey SA 3rd, Zieske HA, Levy MN The essential function of the right ventricle. Am Heart J. 1984 Feb;107(2):404-10. doi: 10.1016/0002-8703(84)90402-2. No abstract available.
Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, Temporelli PL, Arena R Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol. 2013 Nov 1;305(9):H1373-81. doi: 10.1152/ajpheart.00157.2013. Epub 2013 Aug 30.
Guazzi M, Borlaug BA Pulmonary hypertension due to left heart disease. Circulation. 2012 Aug 21;126(8):975-90. doi: 10.1161/CIRCULATIONAHA.111.085761. No abstract available.
Guazzi M, Dixon D, Labate V, Beussink-Nelson L, Bandera F, Cuttica MJ, Shah SJ RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes. JACC Cardiovasc Imaging. 2017 Oct;10(10 Pt B):1211-1221. doi: 10.1016/j.jcmg.2016.12.024. Epub 2017 Apr 12.
Guazzi M, Naeije R Pulmonary Hypertension in Heart Failure: Pathophysiology, Pathobiology, and Emerging Clinical Perspectives. J Am Coll Cardiol. 2017 Apr 4;69(13):1718-1734. doi: 10.1016/j.jacc.2017.01.051.
Haddad F, Doyle R, Murphy DJ, Hunt SA Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008 Apr 1;117(13):1717-31. doi: 10.1161/CIRCULATIONAHA.107.653584. No abstract available.
Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014 Dec 21;35(48):3452-62. doi: 10.1093/eurheartj/ehu193. Epub 2014 May 29.
Poels EM, da Costa Martins PA, van Empel VP Adaptive capacity of the right ventricle: why does it fail? Am J Physiol Heart Circ Physiol. 2015 Apr 15;308(8):H803-13. doi: 10.1152/ajpheart.00573.2014. Epub 2015 Feb 13.
Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8. doi: 10.1016/j.echo.2010.05.010. No abstract available.
Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ Mechanisms of right heart failure-A work in progress and a plea for failure prevention. Pulm Circ. 2013 Jan;3(1):137-43. doi: 10.4103/2045-8932.109957. No abstract available.
Right Ventricular Dysfunction in Chronic Heart Failure: Clinical Laboratory and Echocardiographic Characteristics
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.